

ASX Announcement

28 September 2026

Date of 2026 Annual General Meeting and closing date for director nominations

Sydney, Australia, 28 September 2026: Cambium Bio Limited (ASX:CMB) ("Cambium Bio" or "Company") advises, in accordance with ASX Listing Rule 3.13.1, that its 2026 Annual General Meeting ("AGM") will be held online on **Monday, 9 November 2026 at 11:00 am (Sydney time)**.

Director nominations

In accordance with rule 3.5 of the Company's Constitution and ASX Listing Rule 14.3, the Board has determined that the closing date for the receipt of nominations from shareholders of candidates for election as a director at the AGM is 5:00 pm (Sydney time) on Friday, 2 October. A nomination must be received at the Company's registered office, Unit 2.06, 31 Lexington Drive, Bella Vista NSW 2153, or by email to info@cambium.bio, by that time, together with the candidate's signed consent to act as a director.

Notice of Meeting

The Notice of Meeting, including the resolutions relating to the conditional placement announced on 16 September 2026 and the independent expert's report, is expected to be dispatched to shareholders in early October 2026 following ASX review. Shareholders will be able to attend, ask questions and vote at the AGM through the online meeting platform, details of which will be set out in the Notice of Meeting.

– ENDS –

About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is

being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialisation, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

Authorisation & Additional Information

This announcement was authorised for release by the Board of Directors of Cambium Bio Limited.

For further information, please contact:
Acclime Australia – Company Secretary
Email: info@cambium.bio